Rais of Tatarstan visits KFU and Izvarino Pharma’s joint venture, Sever Pharmaceuticals
In July 2025, the plant received a license from the Ministry of Industry and Trade of Russia for the production of pharmaceutical substances by organic synthesis. Kazan Federal University, in turn, provided premises for the localization of the enterprise and provided the competencies of scientists involved in scientific research and development.
Accompanied by the Rector Lenar Safin and General Director of Izvarino Pharma Orest Ibragimov, Rais Rustam Minnikhanov inspected the quality assurance department, the biological synthesis site and the pilot production site, where he got acquainted with the technology. Also, the governor launched production at the chemical synthesis site by symbolically pressing a button on the control panel.
Sergey Yushko, General Director of Sever Pharmaceuticals LLC, emphasized that the Sever project is unique due to its flexibility and high level of automation, and the production concept of the enterprise is focused on the complete protection of personnel and the environment.
“At all stages – from raw material acceptance and sampling to packaging and quality control – the technology of completely contactless interaction of the operator with the product is implemented. Modern isolators, sealed transfer stations, contactless powder loading and unloading systems are used, including in the analytical laboratory during sample preparation,” he explained. “Also, such a safe launch of the production of vital drugs became possible due to our neighborly cooperation with the Kazan Kazanorgsintez. The production is located in the sanitary protection zone of KOS. This enterprise uses modern environmentally friendly technological solutions and does not affect the release of pharmaceutical products. An independent examination confirmed the possibility of such close proximity, which allowed the company to start producing drugs at this site.”
It should be noted that the biosynthesis section at the production facility allows, in terms of its capacity, to cover the needs of the entire Russian and the Eurasian Economic Union markets for the drug Tacrolimus. This drug is an immunosuppressant widely used to prevent transplant rejection. It is included in the list of vital and essential drugs of Russia and is of strategic importance for the healthcare system.
The second important area of the enterprise’s activity is the production of active pharmaceutical substances by chemical synthesis, with their subsequent isolation and purification.
The venture comprises a closed production cycle (from strain to finished substance) and independence from external supplies for a critically important drug.
In addition, Sever is the development center in biological and organic synthesis for Kazan Federal University.